Effectiveness of Tocilizumab after switching from intravenous to subcutaneous formulation in patients with rheumatoid arthritis – a single centre experience
Abstract
Abstract
Appropriate control of rheumatoid arthritis (RA) involves today the absence of clinical disease activity, joint destruction delayed for as long as possible, and adequate quality of life of the affected. With currently available therapeutic modalities, this therapeutic goal can be achieved in a large number of patients.
The aim of this research was to determinated the effectiveness of an IL-6 blocker (Tocilizumab) in patients with RA in everyday clinical practice. We also analyzed whether a change in drug administration (switching from intravenous to subcutaneous drug formulation) had an impact on drug effectiveness (using the DAS 28 SE and CDAI indexes) and quality of life of patients with RA (HAQ, Beck Depression Inventory, FACIT F score and SF 36 questionnaire). The study included 53 subjects diagnosed with RA, treated with Tocilizumab.
After a 6 months' follow-up and use of subcutaneous Tocilizumab, we concluded that the method of drug administration did not have an impact on its effectiveness and on all the examined parameters of quality of life assessment.
References
1. Zlatković-Švenda, M.I., Stojanović, R.M., B. Šipetić-Grujičić, S. et al. Prevalence of rheumatoid arthritis in Serbia. Rheumatol Int 34, 649–658 (2014).
https://doi.org/10.1007/s00296-013-2897-7
2. Smolen JS, Landewé RBM, Bijlsma JWJ, et alEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 updateAnnals of the Rheumatic Diseases 2020;79:685-699
http://dx.doi.org/10.1136/annrheumdis-2019-216655
3. Burmester GR, Rubbert-Roth A, Cantagrel A, et al. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA); AnnRheum Dis 2016;75:68–74.
http://dx.doi.org/10.1136/annrheumdis-2015-207281
4. Darloy J, Segaud N, Salmon HJ et al. Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study; Rheumatol Ther (2019) 6:61–75
https://doi.org/10.1007/s40744-018-0138-y
5. Prevoo ML, van 't Hof MA, Kuper HH, et. al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995 Jan;38(1):44-8. PMID: 7818570
https://doi.org/10.1002/art.1780380107
6. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care, Best Practice & Research Clinical Rheumatology 2007; vol 21 (4): 663-675
https://doi.org/10.1016/j.berh.2007.02.004
7. Maska L, Anderson J, Michaud K. Measures of Functional Status and Quality of Life in Rheumatoid Arthritis, Arthritis Care & Research 2011; 63 (S11): 4-13.
https://doi.org/10.1002/acr.20620
8. Margaretten M., Julian L., Katz P, Yelin E. Depression in patients with rheumatoid arthritis: description, causes and mechanisms. International journal of clinical rheumatology 2011; 6 (6), 617–623.
https://doi.org/10.2217/IJR.11.6
9. Webster K, Cella D and Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation; Health and Quality of Life Outcomes 2003, 1:79-85.
https://doi.org/10.1186/1477-7525-1-79
10. Ware JE, Shelbourne CD. The MOS 36-item Short Form Health Survey (SF-36): conceptual framework and item selection. Med Care. 1992; 30 (6):473-83.
http://www.jstor.org/stable/3765916
11. Matcham F, Rayner L, Steer S, et al. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology 2013; 52:2136–48.
https://doi.org/10.1093/rheumatology/ket169
12. Geenen R, Dures E, A biopsychosocial network model of fatigue in rheumatoid arthritis: a systematic review, Rheumatology, 2019; 58 (5):v10-v21,
https://doi.org/10.1093/rheumatology/kez403
13. Fusama M, Nakahara H, Hamano Y. et al. Improvement of health status evaluated by Arthritis Impact Measurement Scale 2 (AIMS-2) and Short Form-36 (SF-36) in patients with rheumatoid arthritis treated with tocilizumab. Mod Rheumatol. 2013 Mar;23(2):276-83. doi: 10.1007/s10165-012-0674-1.
https://doi.org/10.3109/s10165-012-0674-1